Literature DB >> 22495780

Generation n + 1: Projected numbers of babies born to women with PKU compared to babies with PKU in the United States in 2009.

Robert Resta1.   

Abstract

Newborn PKU screening has been available since the mid-1960s, and the first group of screened babies is now a complete reproductive cohort (age 15-44). Untreated maternal PKU (MPKU) often results in significant developmental and physical disabilities in exposed fetuses, and could potentially offset some or all of the benefits produced by newborn PKU screening and dietary treatment. Based on the age distribution of the United States population in 2009, and using different estimates of PKU frequency (1/10,000; 1/15,000; 1/20,000), the projected number of babies born to women with PKU was compared to the projected number of babies born with PKU. In 2009, there were about 62,000,000 women age 15-44, with a fertility rate of 66.7 births/1,000 women. Of these women, depending on the incidence of PKU, 3,097-6,195 were estimated to have PKU, and they would have delivered 207-413 babies. In that same year, the number of births was 4,118,055, which would have resulted in 206-412 babies with PKU. Thus, in the United States, at all estimates of PKU frequency, the number of babies exposed to MPKU is equal to the number of babies born with PKU. This ratio varies with the fertility rate but is not dependent on the incidence of PKU. The benefits of newborn PKU screening and treatment could be significantly curtailed if adequate resources, education, and funding are not available to follow and monitor women with MPKU and their babies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22495780     DOI: 10.1002/ajmg.a.35312

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Breastfeeding infants with phenylketonuria in the United States and Canada.

Authors:  Sandra A Banta-Wright; Nancy Press; Kathleen A Knafl; Robert D Steiner; Gail M Houck
Journal:  Breastfeed Med       Date:  2013-12-18       Impact factor: 1.817

2.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

3.  Low increase in phenylalanine tolerance during pregnancies in PKU woman with high prepregnancy BMI and postconceptional initiation of diet: A case report.

Authors:  Joanna Żółkowska; Kamil Hozyasz
Journal:  Int J Reprod Biomed       Date:  2019-11-07

4.  Preventing maternal phenylketonuria (PKU) syndrome: important factors to achieve good metabolic control throughout pregnancy.

Authors:  Carmen Rohde; Alena Gerlinde Thiele; Christoph Baerwald; Rudolf Georg Ascherl; Dinah Lier; Ulrike Och; Christina Heller; Alexandra Jung; Kathrin Schönherr; Monika Joerg-Streller; Simone Luttat; Sabine Matzgen; Tina Winkler; Stefanie Rosenbaum-Fabian; Oxana Joos; Skadi Beblo
Journal:  Orphanet J Rare Dis       Date:  2021-11-18       Impact factor: 4.123

5.  Ten years of specialized adult care for phenylketonuria - a single-centre experience.

Authors:  Ulrike Mütze; Alena Gerlinde Thiele; Christoph Baerwald; Uta Ceglarek; Wieland Kiess; Skadi Beblo
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

6.  Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.